The White House approved NIH apportionments, ending a months‑long OMB hold and allowing the agency to resume grant awards, hiring and program rollouts for fiscal 2026. NIH Director Jayanta Bhattacharya confirmed funds will be distributed and new grants will begin to flow after congressional pressure. The move restores momentum for institutional research pipelines that had been stalled. Separately, Congress passed a five‑year reauthorization of SBIR/STTR programs, reinstating critical early‑stage grant funding for small biotech ventures. BIO and industry groups welcomed the reauthorization as a stabilizing step for seed‑stage translational work; agencies will reopen solicitations once administrative processes are completed. Together, the NIH clearance and SBIR reauthorization remove key near‑term funding bottlenecks for academic labs and small biotechs.